Skip to content

Evaluation of the Picosure 755nm Alexandrite Laser With Lens Array for the Treatment of Acne Scars

Evaluation of the Picosure 755nm Alexandrite Laser With Lens Array for the Treatment of Acne Scars

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02103127
Enrollment
20
Registered
2014-04-03
Start date
2013-07-31
Completion date
2015-05-31
Last updated
2021-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Scars

Brief summary

The purpose of this study is to assess treatment of facial acne scars using the 755nm Alexandrite Laser with lens arrays.

Interventions

DEVICE755nm Alexandrite laser with lens array

Sponsors

Cynosure, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Is a healthy male or female between 18 and 65 years old 2. Has unwanted acne scars, excluding ice pick scars (Deep atrophic scars that resemble poked holes), and wishes to undergo laser treatments. 3. Is willing to consent to participate in the study. 4. Is willing to comply with all requirements of the study including biopsies, being photographed, following post treatment care and attending all treatment and follow up visits.

Exclusion criteria

1. The subject is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period. 2. The subject is hypersensitive to light exposure OR takes photo sensitized medication. 3. The subject has active or localized systemic infections. 4. The subject has a coagulation disorder or is currently using anti-coagulation medication (including but not limited to heavy aspirin therapy {greater than 81 mg per day}). 5. The subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study. 6. The subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 3 months prior to entering this study. 7. The subject has used Accutane within 6 months prior to enrollment. 8. The subject has the need to be exposed to artificial tanning devices or excessive sunlight during the trial. 9. The subject has had prior treatment with parenteral gold therapy (gold sodium thiomalate). 10. The subject has a history of keloids. 11. The subject has evidence of compromised wound healing. 12. The subject has a history of squamous cell carcinoma or melanoma. 13. The subject has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications. 14. The subject has an allergy to lidocaine and epinephrine.

Design outcomes

Primary

MeasureTime frameDescription
Severity Change in Acne ScarringBaseline and 1 month post treatmentThe scale is a Physician Global Scarring Grading Scale, which counts and types scars by tallying up of the number and severity according to an organized grading system, where 0 is the lowest point value and represents no scarring. The theoretical highest score possible is an 84. The change in the score from the baseline to the follow up was collected. A negative change indicates a decrease in points (which indicates improvement).

Secondary

MeasureTime frameDescription
Investigator Satisfaction Questionnaire3 months post treatmentInvestigator will complete satisfaction questionnaire at follow up visits from 0 to 3, where 0 is extremely dissatisfied and 3 is extremely satisfied.
Subject Satisfaction Questionnaire3 months post treatmentSubject will complete satisfaction questionnaire at follow up visits from 0 to 3, where 0 is extremely dissatisfied and 3 is extremely satisfied.

Countries

United States

Participant flow

Participants by arm

ArmCount
755nm Alexandrite Laser With Lens Array
755nm Alexandrite laser with lens array
20
Total20

Baseline characteristics

Characteristic755nm Alexandrite Laser With Lens Array
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
20 Participants
Fitzpatrick Skin Type
Fitzpatrick Skin Score I
0 Participants
Fitzpatrick Skin Type
Fitzpatrick Skin Score II
13 Participants
Fitzpatrick Skin Type
Fitzpatrick Skin Score III
3 Participants
Fitzpatrick Skin Type
Fitzpatrick Skin Score IV
4 Participants
Fitzpatrick Skin Type
Fitzpatrick Skin Score V
0 Participants
Fitzpatrick Skin Type
Fitzpatrick Skin Score VI
0 Participants
Race/Ethnicity, Customized
Race/Ethnicity
African American
0 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Asian
0 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Caucasian
16 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Hispanic
3 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Other
1 Participants
Sex: Female, Male
Female
19 Participants
Sex: Female, Male
Male
1 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 20
other
Total, other adverse events
17 / 20
serious
Total, serious adverse events
0 / 20

Outcome results

Primary

Severity Change in Acne Scarring

The scale is a Physician Global Scarring Grading Scale, which counts and types scars by tallying up of the number and severity according to an organized grading system, where 0 is the lowest point value and represents no scarring. The theoretical highest score possible is an 84. The change in the score from the baseline to the follow up was collected. A negative change indicates a decrease in points (which indicates improvement).

Time frame: Baseline and 1 month post treatment

Population: 1 subject was pregnant, 1 subject was lost to follow up, and 1 subject withdrew consent. 3 subjects missed their visits.

ArmMeasureValue (MEAN)Dispersion
755nm Alexandrite Laser With Lens ArraySeverity Change in Acne Scarring-2 score on a scaleStandard Deviation 2.71
Primary

Severity Change in Acne Scarring

The scale is a Physician Global Scarring Grading Scale, which counts and types scars by tallying up of the number and severity according to an organized grading system, where 0 is the lowest point value and represents no scarring. The theoretical highest score possible is an 84. The change in the score from the baseline to the follow up was collected. A negative change indicates a decrease in points (which indicates improvement).

Time frame: Baseline and 3 months post treatment

Population: 1 subject was pregnant, 1 subject was lost to follow up, and 1 subject withdrew consent.

ArmMeasureValue (MEAN)Dispersion
755nm Alexandrite Laser With Lens ArraySeverity Change in Acne Scarring-1 score on a scaleStandard Deviation 3.15
Secondary

Investigator Satisfaction Questionnaire

Investigator will complete satisfaction questionnaire at follow up visits from 0 to 3, where 0 is extremely dissatisfied and 3 is extremely satisfied.

Time frame: 3 months post treatment

Population: 1 subject was pregnant, 1 subject was lost to follow up, and 1 subject withdrew consent.

ArmMeasureGroupValue (NUMBER)
755nm Alexandrite Laser With Lens ArrayInvestigator Satisfaction QuestionnaireExtremely Satisfied0 participants
755nm Alexandrite Laser With Lens ArrayInvestigator Satisfaction QuestionnaireSatisfied10 participants
755nm Alexandrite Laser With Lens ArrayInvestigator Satisfaction QuestionnaireDissatisfied7 participants
755nm Alexandrite Laser With Lens ArrayInvestigator Satisfaction QuestionnaireExtremely Dissatisfied0 participants
Secondary

Subject Satisfaction Questionnaire

Subject will complete satisfaction questionnaire at follow up visits from 0 to 3, where 0 is extremely dissatisfied and 3 is extremely satisfied.

Time frame: 3 months post treatment

Population: 1 subject was pregnant, 1 subject was lost to follow up, and 1 subject withdrew consent.

ArmMeasureGroupValue (NUMBER)
755nm Alexandrite Laser With Lens ArraySubject Satisfaction QuestionnaireExtremely Satisfied3 participants
755nm Alexandrite Laser With Lens ArraySubject Satisfaction QuestionnaireSatisfied11 participants
755nm Alexandrite Laser With Lens ArraySubject Satisfaction QuestionnaireDissatisfied3 participants
755nm Alexandrite Laser With Lens ArraySubject Satisfaction QuestionnaireExtremely Dissatisfied0 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026